Innate Pharma(IPHA) - 2024 Q4 - Annual Report

Announcement of 2024 Filings This section details the company's recent regulatory filings, including the Universal Registration Document and Form 20-F Universal Registration Document Filing Innate Pharma announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) with the French market authority 'Autorité des Marchés Financiers' (AMF) on April 30, 2025. The document is available on the Company's and AMF's websites - Filing of 2024 Universal Registration Document with the French market authority AMF on April 30, 2025[1] - The document can be downloaded (in French) on the Company's website and on the AMF's website[1] Annual Report on Form 20-F Filing The Company also announced the filing of its annual report on Form 20-F for the year ending December 31, 2024, with the United States Securities and Exchange Commission (SEC) - Filing of annual report on Form 20-F for the year ending December 31, 2024, with the United States Securities and Exchange Commission (SEC)[2] - The report can be accessed on the Company's website and on the SEC's website[2] About Innate Pharma This section provides an overview of Innate Pharma's business, product portfolio, partnerships, and corporate details Company Overview and Business Model Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Its innovative approach harnesses the innate immune system through three therapeutic strategies: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs) - Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients[3] - Innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers (ANKET® platform), Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs)[3] Product Portfolio and Partnerships Innate's portfolio includes several ANKET® drug candidates for various tumor types, IPH4502 (a differentiated ADC for solid tumors), lacutamab (anti-KIR3DL2 mAb for T cell lymphomas), and monalizumab (anti-NKG2A mAb developed with AstraZeneca for non-small cell lung cancer). The company partners with biopharmaceutical companies like Sanofi and AstraZeneca - Portfolio includes ANKET® drug candidates, IPH4502 (ADC), lacutamab (anti-KIR3DL2 mAb), and monalizumab (anti-NKG2A mAb)[4] - Monalizumab is developed with AstraZeneca in non-small cell lung cancer[4] - Trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca[5] Corporate Information Innate Pharma is headquartered in Marseille, France, with a US office in Rockville, MD, and is listed on Euronext Paris and Nasdaq in the US - Headquartered in Marseille, France with a US office in Rockville, MD[5] - Listed on Euronext Paris and Nasdaq in the US[5] Information about Innate Pharma Shares This section provides key identifiers for Innate Pharma's shares, including ISIN, ticker symbols, and LEI Share Identifiers This section provides key identifiers for Innate Pharma's shares, including its ISIN code, ticker symbols on Euronext and Nasdaq, and Legal Entity Identifier (LEI) | Identifier | Value | | :--------- | :---- | | ISIN code | FR0010331421 | | Ticker Euronext | IPH | | Ticker Nasdaq | IPHA | | LEI | 9695002Y8420ZB8HJE29 | Disclaimers and Forward-Looking Statements This section outlines important disclaimers regarding forward-looking information and general legal statements Forward-Looking Information Disclaimer This press release contains forward-looking statements, identifiable by specific terminology, which are subject to numerous risks and uncertainties. These risks, detailed in the Universal Registration Document and Form 20-F, could cause actual results to differ materially and include uncertainties in R&D, clinical trials, regulatory approvals, reliance on third parties, commercialization efforts, and capital raising - The press release contains certain forward-looking statements, identified by words such as "anticipate," "believe," "expect," etc[6] - These statements are subject to numerous risks and uncertainties, including those related to R&D, clinical trials, regulatory approvals, reliance on third parties, commercialization efforts, and ability to raise capital[6] - For additional discussion of risks, refer to the Risk Factors section of the Universal Registration Document and Annual Report on Form 20-F[6] General Disclaimers The company clarifies that website content is for information only and not incorporated by reference into the press release. It also states that forward-looking statements should not be regarded as a warranty of achieving objectives, and the company undertakes no obligation to publicly update them, except as required by law. Furthermore, the press release does not constitute an offer to sell or a solicitation to buy shares - References to the Company's website and the AMF website are for information only, and their content is not incorporated by reference into this press release[7] - Forward-looking statements are not a representation or warranty that the Company will achieve its objectives, and the Company undertakes no obligation to publicly update them, except as required by law[8] - This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma[9] Contacts This section provides contact information for investor relations and media inquiries Investor and Media Contacts This section provides contact information for investors and media relations, including names, phone numbers, and email addresses | Role | Contact Person | Phone Number | Email | | :-------------- | :------------------ | :----------------- | :----------------------------- | | Investors | Henry Wheeler | +33 (0)4 84 90 32 88 | Henry.wheeler@innate-pharma.fr | | Media Relations | Arthur Rouillé (NewCap) | +33 (0)1 44 71 00 15 | innate@newcap.eu |